CDx Diagnostics

Suffern, United States Founded: 1997 • Age: 29 yrs Acquired By Galen Partners
AI-based platform is utilized to detect precancerous tissues in biopsies.
Request Access

About CDx Diagnostics

CDx Diagnostics is a company based in Suffern (United States) founded in 1997 by Mark Rutenberg was acquired by Galen Partners in July 2017.. CDx Diagnostics has raised $16.04 million across 2 funding rounds from investors including Galen Partners. CDx Diagnostics offers products and services including WATS 3D, OralCDx, and EndoCDx. CDx Diagnostics operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and PathAI, among others.

  • Headquarter Suffern, United States
  • Founders Mark Rutenberg
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Technology → Robotics, Automation & Advanced Manufacturing
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Health Technology & Digital Health
Healthcare → Health Technology & Digital Health
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $16.04 M (USD)

    in 2 rounds

  • Latest Funding Round
    $5 M (USD), Series A

    Jun 15, 2020

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Galen Partners

    (Jul 11, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of CDx Diagnostics

CDx Diagnostics offers a comprehensive portfolio of products and services, including WATS 3D, OralCDx, and EndoCDx. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

AI-enabled tool for early detection of precancerous cells in esophagus.

Platform for oral cancer prevention through advanced tissue analysis.

Technology for detecting dysplasia in endoscopic procedures.

People of CDx Diagnostics
Headcount 50-200
Employee Profiles 17
Board Members and Advisors 5
Employee Profiles
People
Amanda Perello
Senior Manager, IT Applications Management
People
Jonathan Justin
Talent Acquisition Lead
People
Tom Bartel
Executive Vice President Of Sales
People
Roger O'Sullivan
General Counsel, Corporate Secretary, Compliance Officer

Unlock access to complete

Board Members and Advisors
people
Thomas A. Bologna
Chairman
people
John Watts
Director
people
Mark Rutenberg
Director
people
David Jahns
Director

Unlock access to complete

Funding Insights of CDx Diagnostics

CDx Diagnostics has successfully raised a total of $16.04M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $5.0M
  • First Round

    (16 Dec 2019)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2020 Amount Series A - CDx Diagnostics Valuation

investors

Dec, 2019 Amount Series A - CDx Diagnostics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in CDx Diagnostics

CDx Diagnostics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Galen Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by CDx Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - CDx Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cdx Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of CDx Diagnostics

CDx Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and PathAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
domain founded_year HQ Location
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
domain founded_year HQ Location
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
domain founded_year HQ Location
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
domain founded_year HQ Location
Therapeutics for aging diseases are developed by targeting senescent cells.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cdx Diagnostics

Frequently Asked Questions about CDx Diagnostics

When was CDx Diagnostics founded?

CDx Diagnostics was founded in 1997 and raised its 1st funding round 22 years after it was founded.

Where is CDx Diagnostics located?

CDx Diagnostics is headquartered in Suffern, United States. It is registered at Suffern, New York, United States.

Is CDx Diagnostics a funded company?

CDx Diagnostics is a funded company, having raised a total of $16.04M across 2 funding rounds to date. The company's 1st funding round was a Series A of $11.04M, raised on Dec 16, 2019.

What does CDx Diagnostics do?

CDx Diagnostics was founded in 1997 and is headquartered in Suffern, United States. The company operates in the healthcare diagnostics sector, focusing on AI-driven technologies for early detection of precancerous conditions. Proprietary WATS3D biopsy platform is employed to identify tissue changes. Key products include OralCDx, a non-invasive oral brush biopsy system, and EndoCDx, a transepithelial laryngeal brush biopsy tool, supporting clinical assessments in oncology-related fields.

Who are the top competitors of CDx Diagnostics?

CDx Diagnostics's top competitors include Juno Therapeutics, Poseida Therapeutics and PathAI.

What products or services does CDx Diagnostics offer?

CDx Diagnostics offers WATS 3D, OralCDx, and EndoCDx.

Who are CDx Diagnostics's investors?

CDx Diagnostics has 1 investor. Key investors include Galen Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available